A simple blood test can tell doctors when it is safe to stop antibiotics in patients recovering from #sepsis, a review has found. The work supported by @NCAlliance_NHS & other GM organisations & co-authored by @darknatter is published in @Anaes_Journal
https://t.co/t68N6QMN2U
Editor’s choice from the February 25 issue.
➡️ Camrelizumab With Chemotherapy in Patients With Early or Locally Advanced TNBC
➡️ Biomarker-Guided Antibiotic Duration for Hospitalized Patients With Suspected Sepsis
➡️ Essential Thrombocythemia: A Review; and more.
https://t.co/kRpTEJttDt
#JAMA #MedicalResearch #ClinicalTrials
@WICSBottomLine@hqva Thank you for this detailed review and comments. We @AdaptSepsis are working on trial process evaluation and health economic outcomes right now, so more to come to aid understanding of results. Hopefully, we will see you all @ICS_updates events in 2025 for further discussions
1/ Delighted to report the results of the Procalcitonin-guided duration of antibiotic treatment in children hospitalised with confirmed or suspected bacterial infection in the UK (BATCH) trial in @LancetChildAdol https://t.co/FI5mzk3A7j
A major UK patient trial of a new biomarker testing protocol for sepsis, led by @OfficialUoM researchers, has shown it is possible to safely stop antibiotic treatment earlier than current care 🔬
@FBMH_UoM@DarkNatter
Read more about the trial 👇
https://t.co/0w0WKwcivz
@darknatter presents the results of the @AdaptSepsis trial results earlier today at @CCRdownunder
The paper has been published in @JAMA_current
https://t.co/BK8lAqLFXd
We are delighted to have contributed to this important trial. Because clinical research is how we improve the care we deliver. Thank you to our patients who took part. @AdaptSepsis@NCAresearchNHS@DarkNatter
Fantastic work led by @darknatter and delivered by the phenomenal UK Critical Care community.
We can safely reduce antibiotic duration using procalcitonin (but not CRP).
@AdaptSepsis@WarwickCTU
We're delighted to announce @AdaptSepsis as our first trial result presentation at #CCRdownunder
ADAPT-Sepsis is a 2760 patient RCT investigating biomarker-guided duration of antibiotic therapy in patients with sepsis
To be presented by @DarkNatter
https://t.co/b4KzFpBA2r
Thrilled to hear that the @AdaptSepsis team have reached their recruitment target - well done everyone!
We're looking forward to comparing our process evaluation findings with your trial results in the coming months! https://t.co/k8azAAe0ZK
Great work to all involved in completing recruitment to the @AdaptSepsis study. Thank you to our research team for their hard work in recruiting 85 of the number below! @NCAresearchNHS@OldhamCO_NHS